Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide
Journal of Breast Cancer 2016³â 19±Ç 1È£ p.8 ~ p.17
³ëÁ¤½Ç(Ro Jung-Sil) - National Cancer Center Breast Cancer Center
(Fiona Tsui-Fen Cheng) - Taiwan Shin Kong Wu Ho-Su Memorial Hospital Breast Cancer Center
(Virote Sriuranpong) - Chulalongkorn University King Chulalongkorn Memorial Hospital Department of Medicine
(Antonio Villalon) - Philippines Manila Doctor Hospital Department of Internal Medicine
(B. K Smruti) - Bombay Hospital Institute of Medical Science Division of Medical Oncology
(Janice Tsang) - University of Hong Kong Queen Mary Hospital Department of Clinical Oncology
(Yap Yoon-Sim) - National Cancer Centre Singapore Department of Medical Oncology
(Asian Working Group for Eribulin Clinical Guide) - ¼Ò¼ÓÈ®ÀÎÁß
Abstract
Eribulin, an antimicrotubule chemotherapeutic agent, is approved for the treatment of pretreated metastatic breast cancer (mBC) based on the positive outcomes of phase II and phase III clinical trials, which enrolled mainly Western patients. Eribulin has recently been approved in an increasing number of Asian countries; however, there is limited clinical experience in using the drug in certain countries. Therefore, we established an Asian working group to provide practical guidance for eribulin use based on our clinical experience. This paper summarizes the key clinical trials, and the management recommendations for the reported adverse events (AEs) of eribulin in mBC treatment, with an emphasis on those that are relevant to Asian patients, followed by further elaboration of our eribulin clinical experience. It is anticipated that this clinical practice guide will improve the management of AEs resulting from eribulin treatment, which will ensure that patients receive the maximum treatment benefit.
Å°¿öµå
Asians, Breast neoplasms, Chemotherapy, Eribulin mesylate
KMID :
1134120160190010008
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
Eribulin is generally well tolerated although neutropenia may occur at a higher frequency among Asian patients receiving eribulin after several lines of systemic therapy.